The PTEN–PI3K pathway: of feedbacks and cross-talks

By Arkaitz Carracedo, P. Pandolfi. Oncogene, 2008

899 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Physiology

View Paper: https://www.semanticscholar.org/paper/1e46860ae757773ddb99824df217b3fa80c74d7e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. David M. Sabatini
2. M. Laplante
3. Timothy R. Peterson
4. Y. Sancak
5. C. Thoreen
6. S. A. Kang
7. Nathanael S. Gray
8. W. Kuehl

In Oncology

1. S. A. Kang
2. C. Thoreen
3. David M. Sabatini
4. Nathanael S. Gray
5. M. Laplante

In Physiology

1. David M. Sabatini
2. M. Laplante

Citations in the corpus

• DEPTOR is an mTOR Inhibitor Whose Frequent Overexpression in Multiple Myeloma Cells Promotes their Survival (2009, background): “As both PC3 and U87 cells lack PTEN (SANGER COSMIC database), a negative regulator of PI3K signaling that controls the responsiveness of the mTORC1 and mTORC2 pathways to growth factors (reviewed in Carracedo and Pandolfi, 2008), it seemed likely that PTEN loss suppresses DEPTOR expression.”
• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023, background): “Thus, PAM pathway mutations in either negative or positive feedback loops can potentially lead to the onset and/or progression of cancer [158, 145] (Fig.”